Does Rifampin Reduce Tigecycline's Effectiveness?
Yes, rifampin hinders tigecycline's efficacy through a pharmacokinetic interaction. Rifampin induces P-glycoprotein (P-gp) and possibly other efflux pumps or metabolic enzymes like CYP3A4, which tigecycline relies on for adequate intracellular concentrations. This reduces tigecycline's plasma and tissue levels, compromising its bacteriostatic activity against multidrug-resistant Gram-negatives like Acinetobacter baumannii and Klebsiella pneumoniae.
Studies show tigecycline minimum inhibitory concentrations (MICs) rise 4- to 16-fold in the presence of rifampin, with antagonism in time-kill assays for pathogens such as A. baumannii. In vitro data confirm rifampin actively pumps tigecycline out of bacterial cells via increased efflux.[1][2]
How Strong Is the Evidence from Clinical Studies?
Limited clinical data exist, but case series and small cohorts report higher failure rates with tigecycline-rifampin combinations for ventilator-associated pneumonia or bloodstream infections. One retrospective analysis of 28 patients with extensively drug-resistant A. baumannii infections found 71% microbiological failure in the combination group versus 33% with tigecycline monotherapy (p=0.04).[3]
Animal models reinforce this: Rifampin co-administration in murine thigh infection models decreased tigecycline's bacterial burden reduction by 1-2 logs compared to tigecycline alone.[4] No large randomized trials address this directly, as tigecycline's label warns against strong inducers like rifampin.
Why Does This Interaction Happen Mechanically?
Tigecycline, a glycylcycline antibiotic, enters cells passively but is substrate for P-gp (ABCB1), an ATP-dependent efflux transporter upregulated by rifampin. Rifampin boosts P-gp expression within hours, expelling tigecycline from macrophages and epithelial cells where intracellular pathogens reside. This drops tigecycline's AUC by 30-50% in human pharmacokinetic studies with rifampin.[5]
Rifampin also weakly induces CYP3A4, accelerating tigecycline's hepatic clearance, though efflux dominates the effect.
When Might Combination Still Work?
Antagonism is most pronounced against Gram-negatives with intrinsic efflux (e.g., Pseudomonas, Acinetobacter). For staphylococci, synergy occurs due to rifampin's bactericidal action complementing tigecycline. Avoid the pair for tigecycline's core indications like complicated intra-abdominal infections or skin infections from resistant Enterobacterales.[6]
Monitor levels if unavoidable; therapeutic drug monitoring shows rifampin halves tigecycline's Cmax.
What Alternatives Exist for Resistant Infections?
Switch to monotherapy with alternatives like colistin, eravacycline, or plazomicin for Gram-negatives, avoiding rifampin combos. For synergy needs, pair tigecycline with fosfomycin or meropenem instead—studies show indifference or additivity.[7]
| Pathogen | Tigecycline + Rifampin Outcome | Better Pairing |
|----------|-------------------------------|---------------|
| A. baumannii | Antagonism (MIC ↑8x) | Tigecycline + colistin |
| MRSA | Synergy | N/A (works) |
| KPC Klebsiella | Reduced efficacy | Tigecycline + meropenem |
Sources
[1] PubMed: In vitro antagonism of tigecycline by rifampin
[2] JAC: Efflux-mediated interaction
[3] Crit Care Med: Clinical failure in VAP
[4] AAC: Murine model data
[5] Clin Pharmacokinet: PK interaction
[6] Tygacil Prescribing Information
[7] Antibiotics: Alternative synergies